Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

NON PROFIT

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Political Squabbles Slow Drug Development for Rare Diseases

FDA-approved clinical trials have historically lacked diversity among the participants. Research shows that as recently as 2021, including during the COVID vaccine clinical trials, about 80% of clinical trial participants were white adults, mostly males, from affluent socioeconomic backgrounds. Trials are often based in majority-white regions of the world. This denies people of color, non-English speaking, underrepresented minorities, and people in low-and-middle-income countries (LMICs), such as India, access to critical life-saving therapies and clinical trials related to rare and common diseases

BioInnovation Institute Announces MNew cohort of Companies Entering the Venture Lab Program

Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab program supports business acceleration, scientific and team development, and provides a risk-free convertible loan of EUR 0.5 million plus access to labs and offices at BII’s entrepreneurial ecosystem in the center of Copenhagen.

The Global Virus Network (GVN) Adds the Centre for the AIDS Programme Research in So. Africa (CAPRISA) as Newest Member to Combat Viral Threats

APRISA is a world leader in HIV and SARS-CoV-2 research, positioned in an integral region to pandemics and virus surveillance, and led by a renowned clinical infectious diseases epidemiologist widely recognized for scientific and leadership contributions in AIDS and COVID-19